ANTITUMOR EFFECT OF ERYTHROMYCIN IN MICE
ANTITUMOR EFFECT OF ERYTHROMYCIN IN MICE
复制标题
DOI：
10.1159/000239325
复制
发表时间：
1995-01-01
期刊：
影响因子：
3.3
通讯作者：
NARITA, N
中科院分区：
文献类型：
--
作者：
HAMADA, K;KITA, E;NARITA, N
与媒介物对照小鼠的剂量范围1-10 mg/kg的口服红霉素在1-10 mg/kg的剂量范围为1-10 mg/kg增加了同种异体和合成小鼠系统中承重小鼠的生存时间，与媒介物对照小鼠相比，在5 mg/kg/天的剂量。在肿瘤移植的早期，肿瘤巨噬细胞和天然杀伤细胞活跃于红霉素治疗的小鼠的抗肿瘤耐药性中。此后，随着白细胞介素4（IL4）的血清水平上升，巨噬细胞的肿瘤活性变得更强。此外，用抗IL-4单克隆抗体治疗小鼠，废除了红霉素赋予的抗肿瘤抗性。这些结果表明，红霉素通过增强IL4的产生来增强巨噬细胞的肿瘤活性，从而表现出间接的抗塑性活性。
Oral administration of erythromycin in the dose range of 1-10 mg/kg increased the survival times of tumor-bearing mice in both allogeneic and syngeneic mouse systems by two- to threefold as compared with those of vehicle control mice, with the maximum effect at a dose of 5 mg/kg/day. During the early phase of tumor transplantation, tumoricidal macrophages and natural killer cells were active in the antitumor resistance of erythromycin-treated mice. Thereafter, the tumoricidal activity of macrophages became stronger as serum levels of interleukin-4 (IL4) rose. Furthermore, treatment of mice with anti-IL-4 monoclonal antibody abolished the antitumor resistance conferred by erythromycin. These results indicate that erythromycin exhibits an indirect antineoplastic activity by enhancing the production of IL4 which augments the tumoricidal activity of macrophages.